Skip to main content
OpenTrials
Completed

NCT Number: NCT02527369

Effect of the XP1100RF Therapy on Thighs Circumference Reduction

This study was designed to demonstrate safety and efficacy of the XP1100RF for non-invasive temporary reduction of thighs circumference by disruption of adipocyte cells.

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

This study is a prospective, single-arm, open label study of thighs circumference reduction following 4 treatment sessions delivered once a week over a 4-week period. The objective of the study is to demonstrate the effectiveness of the treatment after 30-day in achieving thighs circumference reduction of ≥1 cm relative to the base line assessment.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body Mass Index (BMI) of 20 to 35 kg/m2.
  • Subjects willing and able to abstain from partaking in any treatments other than the study procedure to promote body contouring and/or weight loss during study participation.
  • Subjects willing and able to maintain his/her regular (pre-procedure) diet and exercise regimen without effecting significant change in either direction during study participation.

Exclusion criteria

  • Implanted electronic device such as a cardiac pacemaker, bladder stimulator, spinal cord stimulator or electrodes for a myoelectric prosthesis, etc.
  • Diabetics dependent on insulin or oral hypoglycemic medications
  • Known cardiovascular disease such as arrhythmias, congestive heart failure
  • Cardiac surgeries such as cardiac bypass, heart transplant surgery, pacemakers.
  • Prior surgical interventions for body sculpting of thighs such as liposuction
  • Medical, physical or other contraindications for body sculpting/ weight loss
  • Current use of medication known to affect weight levels and/or cause bloating or swelling and for which abstinence during the course of study participation is not safe or medically prudent
  • Any medical condition known to affect weight levels and/or to cause bloating or swelling
  • Active infection, wound or other external trauma to the area to be treated
  • Pregnant, breast feeding, or planning pregnant before the end of the study
  • Serious mental health illness
  • Active or recurrent cancer or current chemotherapy and/or radiation treatment
  • Negative affection to heat

Treatment and study plan

XP1100RF

Device

Treatment of adipose tissue within the fat layer with XP1100RF device.

Primary outcomes

  1. Thighs Circumference Reduction from Baseline at 30 days Follow Up

    Time frame: 30 days Follow Up

    The primary efficacy outcome measure is set to be a minimum of 80% of subjects at 30-day follow up evaluation to show thighs circumference reduction of ≥1 cm below the gluteal fold relative to the base line assessment.

Secondary outcomes

  1. Adverse Events

    Time frame: 30 days Follow Up

    Absence of adverse events (AE) associated with the treatment procedure. Safety evaluations of skin reaction in the treatment area would be conducted at every treatment and follow up visits.

  2. Adverse Events

    Time frame: 3 months Follow Up

    Absence of adverse events (AE) associated with the treatment procedure. Safety evaluations of skin reaction in the treatment area would be conducted at every treatment and follow up visits.

  3. Subject satisfaction assessed by questionnaires

    Time frame: 30 days Follow Up

    Subject satisfaction as assessed by questionnaires administered at 30 days follow up.

Sponsors and collaborators

Lead sponsor

BTL Industries Ltd.

Industry

Registry information

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Aug 19, 2015
Registry last updated
Jul 13, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.